AstraZeneca has entered into a $555 million agreement focused on artificial intelligence to accelerate gene development. The pharmaceutical giant is making a substantial investment in AI to enhance its drug creation process. This strategic move signifies a growing trend within the pharmaceutical industry to leverage AI for more efficient therapeutic development.
The collaboration aims to utilise AI to identify and validate novel drug targets, particularly for diseases of the nervous system. By analysing vast amounts of data, including DNA profiles and protein expression, AI can pinpoint genetic variants that contribute to human diseases. This approach has the potential to significantly reduce the time and costs associated with bringing new drugs to market.
AstraZeneca has been actively forming AI partnerships, committing over $1 billion to various collaborations. These partnerships aim to improve drug discovery, optimise clinical trials, and develop advanced diagnostics. The company views AI as a crucial component in streamlining the patient journey and ultimately eliminating cancer.
